Madison, N.J.-based Quest Diagnostics has completed its previously announced acquisition of two Lewisville laboratory businesses. Med Fusion and Clear Point labs will serve as Quest’s first national center in precision diagnostics for oncology. Terms of the transaction were not disclosed.
According to a statement, the sites will be combined to create a 200,000-square-foot facility in Lewisville. Under the deal, Quest will absorb Med Fusion and Clear Point’s clients and become a “preferred provider to organizations that are formerly owners of one or both of these businesses.” Among them: Baylor Scott & White Health, Texas Oncology, and Pathologists Bio-Medical Laboratories. The new network is reportedly supported by San Francisco-based McKesson Specialty Health, a division of McKesson Corp.
In this venture, Quest will focus on creating sequencing panels to aid therapy selection and monitoring for cancer. Additionally, the center will serve patients in genomic sequencing to see tumor DNA makeup, which medical experts hope “may help a physician select a therapy or clinical trial and monitor response” for patients in North Texas.